Chugai Pharmaceutical Co., Ltd. CHGCY · OTC
$21.20 +3.31% (+$0.68)
Summary
81 / 100 · Bulios Score
What speaks for it
- Out of every 100 JPY of revenue, 35 JPY is left as net profit.
- It earns 24 JPY a year on every 100 JPY of invested capital.
- It holds more cash than debt: ¥387.9B against ¥17.6B.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue growth is slowing: 1.5% a year over the last 3 years against 11% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.5 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 1.5% a year. For the next fiscal year analysts expect revenue to grow by 2.1%. Earnings per share grew by 6.7% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 29 JPY
- Research and development 14 JPY
- Sales and administration 6.4 JPY
- Taxes and other 13 JPY
- Net profit 35 JPY
Net profit, industry median (Drug Manufacturers - General) 14 JPY
Out of every 100 JPY of revenue, 35 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 4.00%
- Paid out of profit
- 86%
- Raised in a row
- 1 year
You receive $0.82 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.